About Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Market Cap
$0.09B
Employees
54
Listed Since
January 30, 2020
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Phone
617-417-5868
Headquarters
ONE MAIN STREET, 14TH FLOOR
CAMBRIDGE, MA 02142
CIK
0001701541